The present study evaluated the clinical efficacy of chemotherapy in combination with cytokine-induced killer (CIK) biotherapy compared to the chemotherapy alone. Fifty-nine advanced non-small cell lung cancer (NSCLC) patients were randomly divided into two groups, group A (chemotherapy, alone, including docetaxel 75 mg/m(2), day 1; cisplatin, 25 mg/m(2), days 1-4, tri-weekly) and group B (chemotherapy plus CIK cell transfusion). Autologous ClK cells were induced from the patients' peripheral mononuclear cells in vitro and separated by cytometry and then transfused back the patients. The host cellular immune function, clinical curative effects and quality of life (QOL) were examined and were compared between the two groups. The host immune ...
Lung cancer is one of the most common cancers and ranks the first in the mortality worldwide. The co...
Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-ind...
Background: In this phase-II pilot study a cisplatin-based treatment was combined with biological ag...
Aim: The aim of this study was to systemically evaluate the therapeutic efficacy of cytokine-induced...
Background: Lung cancer, particularly non-small-cell lung cancer (NSCLC) is the leading cause of can...
Lung cancer, particularly non-small-cell lung cancer (NSCLC) is the leading cause of cancer mortalit...
BACKGROUND: Lung cancer, particularly non-small-cell lung cancer (NSCLC) is the leading cause of can...
Although a great progress has been made in surgery, radiotherapy and chemotherapy for non-small cell...
IntroductionProgrammed cell death-1 (PD-1) inhibition therapy has changed the treatment paradigm of ...
The effects of autologous cytokine-induced killer (CIK) (CD3(+)CD56(+)) cells together with chemothe...
Cytokine-induced killer (CIK) cells are T effector cells generated by monocytes cultured and stimula...
Cytokine-induced killer (CIK) cells are T lymphocytes that have acquired, in vitro, following extens...
Gerhard Hamilton, Adelina Plangger Department of Vascular Surgery, Medical University of Vienna, Vie...
AbstractBackgroundSmall cell lung cancer (SCLC) is the most devastating type of human lung cancer. P...
<p><b>Note:</b> A total of 428 patients were included in the meta-analysis; among these patients, 21...
Lung cancer is one of the most common cancers and ranks the first in the mortality worldwide. The co...
Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-ind...
Background: In this phase-II pilot study a cisplatin-based treatment was combined with biological ag...
Aim: The aim of this study was to systemically evaluate the therapeutic efficacy of cytokine-induced...
Background: Lung cancer, particularly non-small-cell lung cancer (NSCLC) is the leading cause of can...
Lung cancer, particularly non-small-cell lung cancer (NSCLC) is the leading cause of cancer mortalit...
BACKGROUND: Lung cancer, particularly non-small-cell lung cancer (NSCLC) is the leading cause of can...
Although a great progress has been made in surgery, radiotherapy and chemotherapy for non-small cell...
IntroductionProgrammed cell death-1 (PD-1) inhibition therapy has changed the treatment paradigm of ...
The effects of autologous cytokine-induced killer (CIK) (CD3(+)CD56(+)) cells together with chemothe...
Cytokine-induced killer (CIK) cells are T effector cells generated by monocytes cultured and stimula...
Cytokine-induced killer (CIK) cells are T lymphocytes that have acquired, in vitro, following extens...
Gerhard Hamilton, Adelina Plangger Department of Vascular Surgery, Medical University of Vienna, Vie...
AbstractBackgroundSmall cell lung cancer (SCLC) is the most devastating type of human lung cancer. P...
<p><b>Note:</b> A total of 428 patients were included in the meta-analysis; among these patients, 21...
Lung cancer is one of the most common cancers and ranks the first in the mortality worldwide. The co...
Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-ind...
Background: In this phase-II pilot study a cisplatin-based treatment was combined with biological ag...